Research-Article

You have full text access to this OnlineOpen article

Alendronate in the Prevention of Bone Loss After a Fracture of the Lower Leg†

  1. E. Van Der Poest Clement1,
  2. M. Van Engeland2,
  3. H. Adèr3,
  4. J. C. Roos4,
  5. P. Patka2,
  6. P. Lips M.D.1,*

Article first published online: 1 DEC 2002

DOI: 10.1359/jbmr.2002.17.12.2247

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 17, Issue 12, pages 2247–2255, December 2002

Additional Information

How to Cite

Van Der Poest Clement, E., Van Engeland, M., Adèr, H., Roos, J. C., Patka, P. and Lips, P. (2002), Alendronate in the Prevention of Bone Loss After a Fracture of the Lower Leg. J Bone Miner Res, 17: 2247–2255. doi: 10.1359/jbmr.2002.17.12.2247

Author Information

  1. 1

    Department of Endocrinology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

  2. 2

    Department of Traumatology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

  3. 3

    Department of Clinical Epidemiology and Biostatistics, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

  4. 4

    Department of Nuclear Medicine, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

*Department of Endocrinology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

  1. †

    Dr. Lips has been a consultant and received research funding by Merck & Company and Eli Lilly & Company. Dr. van der Poest Clement served on the regional advisory council on “raloxifene” for Eli Lilly & Company and received funding by Merck & Company. All other authors have no conflict of interest.

Publication History

  1. Issue published online: 2 DEC 2009
  2. Article first published online: 1 DEC 2002
  3. Manuscript Accepted: 1 JUL 2002
  4. Manuscript Revised: 12 JUN 2002
  5. Manuscript Received: 5 NOV 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (178K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Toni-Karri Pakarinen, Heikki-Jussi Laine, Heikki Mäenpää, Mika Kähönen, Pentti Mattila, Jorma Lahtela, Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: A prospective randomized trial, Foot and Ankle Surgery, 2013, 19, 2, 121

    CrossRef

  2. 2
    Julie LI-YU, Emmanuel C. PEREZ, Arturo CAÑETE, Lauro BONIFACIO, Lyndon Q. LLAMADO, Romil MARTINEZ, Allan LANZON, Mae SISON, Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines, International Journal of Rheumatic Diseases, 2011, 14, 3
    Direct Link:
  3. 3
    Leila Kolios, Ann Kristin Hoerster, Stephan Sehmisch, Marie Christin Malcherek, Thomas Rack, Mohammed Tezval, Dana Seidlova-Wuttke, Wolfgang Wuttke, Klaus Michael Stuermer, Ewa Klara Stuermer, Do Estrogen and Alendronate Improve Metaphyseal Fracture Healing When Applied as Osteoporosis Prophylaxis?, Calcified Tissue International, 2010, 86, 1, 23

    CrossRef

  4. 4
    Kyu-Tae Hwang, Byeong-Wook Yoo, Yee-Suk Kim, Il-Yong Choi, Young-Ho Kim, Persistency and Change of the Bone Mineral Density with Alendronate Treatment after Hip Fracture, The Journal of the Korean Hip Society, 2010, 22, 4, 312

    CrossRef

  5. 5
    Peter Augat, Lutz Claes, Increased cortical remodeling after osteotomy causes posttraumatic osteopenia, Bone, 2008, 43, 3, 539

    CrossRef

  6. 6
    June Hart Romeo, Juan Ybarra, Hypogonadal Hypogonadism and Osteoporosis in Men, Nursing Clinics of North America, 2007, 42, 1, 87

    CrossRef

  7. 7
    Ville-Valtteri Välimäki, Niko Moritz, Jessica J. Yrjans, Eero Vuorio, Hannu T. Aro, Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute, Bone, 2006, 38, 3, 432

    CrossRef

  8. 8
    T. Armingeat, R. Brondino, T. Pham, V. Legré, P. Lafforgue, Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study, Osteoporosis International, 2006, 17, 11, 1659

    CrossRef

  9. 9
    Uri A Liberman, Long-Term Safety of Bisphosphonate Therapy for Osteoporosis, Drugs & Aging, 2006, 23, 4, 289

    CrossRef

  10. 10
    Anna M. Sawka, Lehana Thabane, Alexandra Papaioannou, Amiram Gafni, David A. Hanley, Jonathan D. Adachi, A Systematic Review of the Effect of Alendronate on Bone Mineral Density in Men, Journal of Clinical Densitometry, 2005, 8, 1, 7

    CrossRef

  11. 11
    Jennifer J Kelly, Arnold M Moses, Osteoporosis in men: the role of testosterone and other sex-related factors, Current Opinion in Endocrinology & Diabetes, 2005, 12, 6, 452

    CrossRef

  12. 12
    Ryosuke Inoue, Nori-aki Matsuki, Gao Jing, Takashi Kanematsu, Kihachiro Abe, Masato Hirata, The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K–Akt–NFκB pathway in osteosarcoma cells, British Journal of Pharmacology, 2005, 146, 5
    Direct Link:
  13. 13
    Gideon Rodan, Alfred Reszka, Ellis Golub, René Rizzoli, Bone safety of long-term bisphosphonate treatment, Current Medical Research and Opinion, 2004, 20, 8, 1291

    CrossRef

  14. 14
    Craig FJ Munns, Frank Rauch, Leonid Zeitlin, François Fassier, Francis H Glorieux, Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate, Journal of Bone and Mineral Research, 2004, 19, 11
    Direct Link:
  15. 15
    Yvonne Zehnder, Simone Risi, Dieter Michel, Hans Knecht, Romain Perrelet, Marius Kraenzlin, Guido A Zäch, Kurt Lippuner, Prevention of Bone Loss in Paraplegics Over 2 Years With Alendronate, Journal of Bone and Mineral Research, 2004, 19, 7
    Direct Link:
View Full Article (HTML) Get PDF (178K)